Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Perfect arbitrage

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jul 05, 2023 3:22pm

166 Views

Post# 35527866

RE:RE:Perfect arbitrage

That is what I would expect with continued trial success, Fox. Conditional on success, I would guess we are worth at least a third of Immunometics, maybe more if we wait longer for more CAR-T, and OS data on panc mBC and maybe CRC. All my own opinion.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China